JAMA editors call for new FDA monitoring office
have used the pages of their publication to call for the independent monitoring of drugs, after they are on the market, by an office separate and independent from the FDA.
"It is unreasonable to expect that the same agency that was responsible for approval of drug licensing and labeling would also be committed to actively seek evidence to prove itself wrong," JAMA editors wrote in their Dec. 1 issue. "One option worth strong consideration...is to establish an independent drug safety board or independent agency for drug safety, specifically to oversee postmarketing surveillance for drugs and devices" The FDA has drawn similar criticism in recent weeks following testimony
on Capitol Hill regarding the withdrawal of Vioxx.